Wall Street Zen Downgrades Medpace (NASDAQ:MEDP) to Hold

Medpace (NASDAQ:MEDP) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

MEDP has been the subject of a number of other reports. Royal Bank Of Canada reduced their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research report on Friday, February 13th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their price objective for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Leerink Partners reduced their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $467.08.

Medpace Trading Up 4.4%

Shares of MEDP opened at $410.54 on Friday. The company has a market cap of $11.73 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 1.85 and a beta of 1.39. Medpace has a 1-year low of $284.10 and a 1-year high of $628.92. The company’s fifty day simple moving average is $470.61 and its 200 day simple moving average is $535.72.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period in the previous year, the company earned $3.67 earnings per share. The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts forecast that Medpace will post 17.05 earnings per share for the current year.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

Institutional investors have recently modified their holdings of the business. Quent Capital LLC bought a new stake in shares of Medpace in the third quarter valued at about $25,000. Optiver Holding B.V. bought a new stake in shares of Medpace in the third quarter valued at about $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace in the fourth quarter valued at about $30,000. Elyxium Wealth LLC bought a new stake in shares of Medpace in the fourth quarter valued at about $30,000. Finally, Quarry LP bought a new stake in shares of Medpace in the third quarter valued at about $35,000. Institutional investors own 77.98% of the company’s stock.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 beat and raised outlook — Medpace reported Q1 EPS of $4.28 and revenue of $706.6M, both above consensus, and gave FY2026 EPS guidance of $16.68–$17.50. Strong revenue growth and guidance are the primary bullish catalyst. Article Title
• Positive Sentiment: Analyst support remains — Robert W. Baird kept an Outperform rating with a $477 target (still implying upside), providing some analyst backing despite volatility. Article Title
• Positive Sentiment: Technical/buy‑the‑dip narratives — Some outlets note MEDP moved into oversold territory after recent selling, which can attract short‑term bargain hunters. Article Title
• Neutral Sentiment: Short‑interest data unclear — April short‑interest reporting shows effectively 0 days to cover based on the provided figure, an anomalous data point that appears neutral until clarified by exchanges/brokers.
• Neutral Sentiment: Backlog conversion but rising cancellations — Management highlighted roughly $1.94B of backlog conversion over 12 months, but cancellation rates have increased; this is a mixed operational signal that could either load revenue or indicate instability in bookings. Article Title
• Negative Sentiment: Multiple securities‑fraud class action notices filed and law‑firm solicitations — Several firms have announced lawsuits and are soliciting lead‑plaintiff motions with a June 8, 2026 deadline, increasing legal and investor‑sentiment risk. This is a material near‑term overhang. Article Title
• Negative Sentiment: Analyst caution and downgrades tied to cancellations/elevated costs — Some analysts cut stance or reduced price targets citing the spike in backlog cancellations and higher direct costs (e.g., Seeking Alpha coverage and a BMO price‑target cut to $400), which can pressure sentiment and valuation. Article Title
• Negative Sentiment: Executive departure — Medpace’s president announced his resignation after 18 years, adding leadership transition risk at a sensitive time. Article Title

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.